Highlights from ESMO 2025

In this week’s VJOncology podcast, leading experts share key updates presented at the ESMO 2025 Congress in Berlin, Germany. Sara Tolaney, MD, MPH, highlights the expanding role of ADCs in earlier lines of metastatic breast cancer, presenting data from the DESTINY-Breast09 and ASCENT-03 trials, and discusses results from DESTINY-Breast05, where trastuzumab deruxtecan demonstrated superior outcomes to trastuzumab emtansine in high-risk HER2-positive early breast cancer. Scott Tagawa, MD, reports findings from the PSMAddition trial of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer, showing improved radiographic progression-free survival. Antonio Passaro, MD, PhD, outlines data from the OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutated NSCLC, establishing a new benchmark for TROP2-directed ADCs. Andrea Necchi, MD, discusses interim results from the RC48-C016 trial supporting disitamab vedotin plus toripalimab in HER2-expressing urothelial carcinoma, and Sapna Patel, MD, shares encouraging early findings on PRAME-directed TCR therapy in uveal melanoma.